-
Americas
-
Asia & Oceania
-
A-I
J-Z
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Regions
-
Americas
-
Asia & Oceania
-
Europe
-
Middle East & Africa
-
Americas
-
Asia & Oceania
-
Europe
Europe
- Adriatic
- Belgium
- Bulgaria
- Czech Republic
- Deutschland
- España
- France
- Greece
- Hungary
- Ireland
- Israel
- Italia
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
SOLUTIONS
-
Research & Development
-
Real World Evidence
-
Commercialization
-
Safety & Regulatory Compliance
-
Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
- Information Partner Services
- Financial Institutions
- Global Public Health
- Government
- Patient Associations
- Payers
- Providers
THERAPEUTIC AREAS
- Cardiovascular
- Cell and Gene Therapy
- Central Nervous System
- GI & Hepatology
- Infectious Diseases and Vaccines
- Oncology
- Pediatrics
- Rare Diseases
- View All
Impacting People's Lives
"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MORE
Harness the power to transform clinical development
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewResearch & Development Quick Links
Real World Evidence. Real Confidence. Real Results.
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWReal World Evidence Quick Links
See markets more clearly. Opportunities more often.
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWCommercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWSafety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWTechnology Quick Links
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
BLOGS, WHITE PAPERS & CASE STUDIES
Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSTHE IQVIA INSTITUTE
An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTS
FEATURED INNOVATIONS
-
IQVIA Connected Intelligence™
-
IQVIA Healthcare-grade AI™
-
IQVIA AI Assistant
-
Human Data Science Cloud
-
IQVIA Innovation Hub
-
Decentralized Trials
-
Patient Experience Solutions with Apple devices
WHO WE ARE
- Our Story
- Our Impact
- Commitment to Public Health
- Code of Conduct
- Sustainability
- Privacy
- Executive Team
NEWS & RESOURCES
Unlock your potential to drive healthcare forward
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
IQVIA AI is Healthcare-grade AI
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MORE
Meet the IQVIA AI Assistant
Your new expert analyst is here. Be at the forefront of data-driven decision-making with a new generative AI tool that enables you to interact with our products and solutions like never before. Get results you can trust, faster.
LEARN MORE
Your healthcare data deserves more than just a cloud.
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
Proven, faster DCT solutions
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
IQVIA Patient Experience Solutions with Apple devices
Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MOREWORKING AT IQVIA
Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORELIFE AT IQVIA
Careers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE
WE’RE HIRING
"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBSBlog
Ready, Set, Go! The Early Dawn of Humira Biosimilars
Feb 06, 2019
Ready: The billion-euro opportunity
In October 2018, AbbVie’s Humira (adalimumab) lost exclusivity in the EU, creating a €3.9bn1 opportunity for biosimilar manufacturers in this region. This is the largest biologic to go off-patent in this generation and so creates an enticing potential for healthcare savings and increased patient access.
In the month before Humira’s loss of exclusivity, the UK posted the largest consumption volume in Europe. Germany and France followed closely and EU52 as a bloc took 68% of Humira usage in the EU.
Set: Seizing the opportunity
Biosimilar manufacturers had been preparing for this moment for years, Exhibit 2 shows eight Marketing Authorisations (MAs) currently registered amongst five of the largest players.
It is not uncommon for a company to register several MAs for the same product for commercial reasons, such as to bypass indication exclusivity variations in member states or to out-licence a product. Sandoz leads the pack with 3 MAs and Exhibit 3 breaks down the indications approved for each product.
Aside from Cyltezo which will not be launching in the EU as Boehringer Ingelheim decided to focus on the US, all products are ready for launch and so the race is on to gain pole position in key markets.
The UK has been a key driver for biosimilar uptake amongst the top five EU countries by implementing centralised policies favouring switches to the best value biologic. For adalimumab, NHS England was proactive in preparing a special framework to ensure all procurement specialists and hospitals were ready to adopt the biosimilars.
NHS England diligently structured a centralised tender3 designed to:
- Split the market into 11 regions
- Award market access to multiple bidders, ensuring fair and sustainable distribution
- Retain originator Humira availability throughout the first framework
- Ensure a citrate-free biosimilar version is available (after feedback from patients)
The purpose was to ensure no single supplier could be awarded the whole market and provide a strong incentive for suppliers to offer their best price. Exhibit 4 shows the available market to each player with:
- Samsung Bioepis/Biogen awarded nearly 45% of the English market
- Runners-up Amgen and Sandoz have roughly equal access to 50% of England
- Mylan/Fujifilm Kyowa Kirin awarded South London representing 5% of England
Go! Fighting for Market Share
As of November 2018, the first round of products launched across Europe and early indications show Samsung and Amgen have the upper hand in country coverage.
In total, there are 14 countries with adalimumab biosimilar usage. Germany leads the pack with four adalimumab biosimilars already in circulation. The UK, the largest market by volume, has launches from both Samsung and Amgen, who are battling to win 70% of England between them.
In Germany, Humira originator patient numbers fell in November compared to September (which remained flat across the previous year) as physicians switched them out to other products. Tellingly, the largest recipients of these patients were the biosimilars, with Samsung and Sandoz initial winners in the German market.
Winners and Losers
On the dawn of the biggest biosimilar event to date, it is difficult with limited data to nominate who will reap long term success in the battle for autoimmune market share.
Some early patterns are emerging that show Samsung and Amgen have been fast off the mark in key market launches. It is Samsung with Imraldi that has won out so far in the two markets that matter the most: Samsung has the largest potential market in the UK and has shown the most success in acquiring Humira patients in Germany.
It’s important not to lose sight of the finishing line. If the policies put in motion by EU member states provide budget relief that can be converted into increased access, ultimately it would make patients the real victors of this billion-euro opportunity.
For more information on biosimilars, please reach out to me through email.
1 IQVIA MIDAS MAT Q3 2018
2 EU5 countries defined as UK, Germany, France, Spain, Italy
3 https://www.sps.nhs.uk/articles/rmoc-briefing-on-adalimumab-december/